Joan Brugge, PhD, Harvard Medical School
Kris C. Wood, PhD, Duke University
Hilton Denver Inverness
200 Inverness Drive West
Englewood, CO 80112
Meeting #: Refer to your packet.
Hours: 8:00am – 8:00 pm EST M-F
International : 623-516-6140
Drug resistance limits the depth and duration of clinical responses to most anticancer therapies, including targeted therapies. This fact has motivated intense efforts in recent years to define the mechanisms of resistance to commonly used anticancer drugs based on the hope that by doing so, it will be possible to design new therapies that block these mechanisms and thereby circumvent resistance. In fact, the 2013 Forbeck Forum on Resistance Mechanisms, led by Joan Brugge, Ph.D. and Jeff Engelman, M.D., Ph.D., explored precisely this topic. Unfortunately, we now know that many diverse resistance mechanisms can exist for each drug, and these mechanisms often co-occur within individual patients. As a result, efforts to improve therapeutic responses by blocking individual resistance mechanisms have largely failed, while efforts to block combinations of resistance mechanisms have been limited by toxicities.
In light of this challenge, emerging studies in the field are seeking to identify creative and fundamentally new strategies to circumvent resistance. These strategies include identifying common downstream signaling nodes shared by many or all major resistance mechanisms; profiling resistant cells to identify “collateral sensitivities” – vulnerabilities caused by evolutionary trade-offs made by cancer cells along the path to resistance; defining drug combinations with non-overlapping resistance landscapes, and exploring the possibility of individually targeting discrete subclones. Already these studies have yielded compelling results. However, they have largely been performed in isolation from one another. Now is, therefore, an opportune time to gather experts in the field working on the problem of heterogeneous resistance to discuss and critically examine these emerging strategies with the goal of identifying key areas for focus and collaboration.
|Saurav Bandyopadhyay, PhD||University of California, San Francisco|
|Alberto Bardelli, PhD||University of Torino|
|Trever Bivona, MD, PhD||University of California, San Francisco|
|Joan Brugge, PhD||Harvard Medical School|
|Christina Curtis, PhD, MSc||Stanford University|
|Nick Haining, BCh, BM||Merck|
|Christine Lovly, MD, PhD||Vanderbilt University|
|Ira Mellman, PhD||Genetech|
|Gordon Mills, MD, PhD||Oregon Health and Science University|
|Nick Navin, PhD||MD Anderson|
|Kornelia Polyak, MD, PhD||Dana Farber Cancer Institute|
|Sydney Shaffer, MD, PhD||University of Pennsylvania|
|Charles Swanton, MBPhD, FRCP, FMedSci||The Francis Crick Institute|
|Kris Cameron Wood, PhD||Duke University|
|Kirsten Bryant, PhD||University of North Carolina, Chapel Hill|
|Cihangir Duy, PhD||Weill Cornell Medicine|
|Peter Winter, PhD||Massachusetts Institute of Technology|
Denver International Airport (DEN) is the preferred airport as it is only 30 minutes from the meeting location.
The abstracts should be only one or two paragraphs outlining the theme of your presentation and should reflect the objective and spirit of the meeting (see above). Abstracts will be circulated about one week before the meeting. The meeting organizer will start requesting them a month before the meeting.Submit Abstract
For more than 30 years, the Forbeck Foundation has proven to be an excellent steward of donor funds and has remained focused on executing its mission. Interested in sponsoring this Forum? Contact us today for more information!